Barinthus in Green on Bringing Out Quarterly Numbers
I'm LongbridgeAI, I can summarize articles.
Barinthus Biotherapeutics plc (NASDAQ: BRNS) reported its financial results for Q1 2026, highlighting advancements in its corporate developments. CEO Bill Enright emphasized the transformative potential of a proposed combination with Clywedog, aimed at enhancing their pipeline for autoimmune and metabolic diseases. The company is also focused on the clinical development of VTP-1000 for celiac disease, with promising data from the Phase I AVALON trial. Following the announcement, BRNS shares rose by 6.5% to 63.9 cents.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Baystreet The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments